Drug profile

The FDA adverse-event record for Sebelipase Alfa Strength Indicated Is For Final Drug Product And Is Not Administered To The Animal

11 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Sebelipase Alfa Strength Indicated Is For Final Drug Product And Is Not Administered To The Animal. See the species affected, top reactions, and outcomes below.

11
adverse-event reports
100.0%
death-coded share
Chicken
most-reported species
11
IGA Animal mortality greater than expected - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
11
Deaths Reported
100.0%
Death Rate

Active Ingredients

Sebelipase Alfa Strength Indicated Is For Final Drug Product And Is Not Administered To The Animal

Administration Routes

Unknown

Species Affected

Chicken 11

Most Affected Breeds

Unknown 11

Most Reported Reactions

IGA Animal mortality greater than expected 11
IGA Animal morbidity greater than expected 9
Found dead 3
Death 2
Death by euthanasia 2
Fracture 2
Unrelated death 1

Outcome Breakdown

Died
9 (50.0%)
Euthanized
9 (50.0%)

Sebelipase Alfa Strength Indicated Is For Final Drug Product And Is Not Administered To The Animal Adverse Event Insights

11 reports name Sebelipase Alfa Strength Indicated Is For Final Drug Product And Is Not Administered To The Animal; 11 recorded a death outcome (100.0% of reported events, not a population-level mortality rate). Active ingredient: Sebelipase Alfa Strength Indicated Is For Final Drug Product And Is Not Administered To The Animal. Administration route: Unknown.

By species: Chicken (11 reports). By breed: Unknown (11).

Leading clinical signs: IGA Animal mortality greater than expected (11), IGA Animal morbidity greater than expected (9), Found dead (3), Death (2). Outcome, 18 coded reports: Died leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.